Abstract Body

Background: Retaining HIV-infected persons in care is important to receiving antiretroviral therapy (ART) and suppressing viral load. Multiple measures of retention are currently in use with no clear gold standard. Identifying which measures are most closely associated with favorable clinical outcomes may inform how we monitor retention in HIV care. Methodology: We conducted a serial cross-sectional analysis of 22,261 adults (≥18-years-old) in 14 NA-ACCORD clinical cohorts between 2006 and 2010. Patients contributed one year of data during their first full calendar year of observation (subsequent to their year of entry into the cohort). Four measures of retention were calculated for each patient in this year: (1) US Department of Health and Human Services (DHHS), ≥1 visit in each half (Jan-Jun and Jul-Dec); (2) Health Resources and Services Administration (HRSA), ≥2 visits separated by ≥90 days; (3) 6-month gap, ≥6 months between sequential visits, with retention defined as no gap; and (4) 3-month visit constancy, number of 3-month intervals with ≥1 visit. Outcomes were: (1) CD4>200 cells/mm3 and (2) HIV RNA ≤200 copies/mL at the last measurement in the year. Poisson regression examined the association between retention measures and the outcomes, adjusting for age, sex, race, HIV risk factor, initial CD4 count, use of ART, and calendar year. Results: Overall, 75% of patients met the DHHS measure, 89% the HRSA, 85% did not have a 6-month gap, and 63% had visits in 3-4 quarters of the year; 84% had CD4 >200 cells/mm3 and 54% had HIV RNA ≤200 copies/mL. Retention measures varied in their associations with the outcomes. (Figure) The DHHS measure was the only metric significantly associated with CD4 >200 cells/mm3 (adjusted prevalence ratio 1.09, 95% CI 1.05-1.13). All measures were significantly and positively associated with HIV RNA ≤200 copies/mL: DHHS (1.31, 1.25-1.37), HRSA (1.25, 1.16-1.34), 6-month gap (1.19, 1.12-1.27), and 3-month visit constancy (1.20, 1.12-1.29 for 2 quarters; 1.36, 1.27-1.45 for 3 quarters; 1.42, 1.33-1.52 for 4 quarters). Comparisons across measures indicate that the DHHS measure was the strongest predictor of both CD4 >200 cells/mm3 and HIV RNA ≤200 copies/mL (p<0.05). Conclusions: Even though prior studies have shown that retention measures are strongly correlated, we demonstrate that measures vary in their association with clinical outcomes early in the course of patients’ care. The DHHS indicator may be the most useful measure to monitor retention in HIV care.